Advertisement

Topics

Novartis, MMV begin patient trial of antimalarial compound in Africa

02:31 EDT 21 Aug 2017 | Pharmaceutical Business Review

Novartis and Medicines for Malaria Venture (MMV) have started a patient trial of antimalarial compound, KAF156, in Africa.

Original Article: Novartis, MMV begin patient trial of antimalarial compound in Africa

NEXT ARTICLE

More From BioPortfolio on "Novartis, MMV begin patient trial of antimalarial compound in Africa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...